3-(3-chlorophenyl)pentanedioic acid | 4759-58-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(3-chlorophenyl)pentanedioic acid
• 英文别名: 3-(3-Chlor-phenyl)-glutarsaeure
• CAS: 4759-58-4
• 化学式: C₁₁H₁₁ClO₄
• mdl: MFCD19355650
• 分子量: 242.659
• InChiKey: IRWLRFZGNLCCTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(3-chlorophenyl)pentanedioic acid 在 乙酰氯 作用下， 反应 2.0h， 以8.5 g的产率得到3-<3-Chlor-phenyl>-glutarsaeure-anhydrid
  参考文献：
  名称：

  假肽胍-胍催化前手性三酰基胺的对映选择性去对称化

  摘要：

  已经在不对称有机催化中探索了具有C s对称性的三酰基胺，从而在具有弱配位阴离子的手性假肽胍-胍盐的催化下通过甲醇分解开发了一种新的催化对映选择性去对称化前手性三酰基胺。这种有机催化方法为合成有用的具有 1,5-二羰基部分的手性酰亚胺酯提供了一种有效的方法，其合成潜力已在两种 GABA 类似药物的不对称合成中得到体现，( R )-巴氯芬·HCl 和 ( S )-普瑞巴林。

  DOI：

  10.1021/acs.orglett.2c02785
• 作为产物：
  描述：

  2-<3-Chlor-phenyl>-4-hydroxy-4-methyl-6-oxo-cyclohexan-1,3-dicarbonsaeure-diethylester 在 sodium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 反应 2.0h， 生成 3-(3-chlorophenyl)pentanedioic acid
  参考文献：
  名称：

  4-Benzimidazolyl-3-Phenylbutanoic Acids As Novel Pif-Pocket-Targeting Allosteric Inhibitors of Protein Kinase PKCζ

  摘要：

  Protein kinase inhibitors with an allosteric mode of action are expected to reach, in many cases, higher selectivity for the target enzyme than ATP-competitive compounds. Therefore, basic research is aiming at identifying and establishing novel sites on the catalytic domain of protein kinases which might be targeted by allosteric inhibitors. We previously published the first structure-activity relationships (SARs) for allosteric activators of protein kinase PDK1. Here, we present the design, synthesis, and SAR data on a series of novel compounds, 4-benzimidazolyl-3-phenylbutanoic acids, that inhibit the atypical protein kinace C (PKC) zeta via binding to the PIF-pocket. Key positions were identified in the compounds that can be modified to increase potency and selectivity. Some congeners showed a high selectivity toward PKC zeta, lacking inhibition of the most closely related isoform, PKCl, and of further AGC kinases. Furthermore, evidence is provided that these compounds are also active toward cellular PKC zeta without loss of potency compared to the cell-free assay.

  DOI：

  10.1021/jm2005892

文献信息

• Stereoselective Synthesis of Cyclohexanes via an Iridium Catalyzed (5 + 1) Annulation Strategy
  作者：Wasim M. Akhtar、Roly J. Armstrong、James R. Frost、Neil G. Stevenson、Timothy J. Donohoe

  DOI：10.1021/jacs.8b07776

  日期：2018.9.26

  An iridium catalyzed method for the synthesis of functionalized cyclohexanes from methyl ketones and 1,5-diols is described. This process operates by two sequential hydrogen borrowing reactions, providing direct access to multisubstituted cyclic products with high levels of stereocontrol. This methodology represents a novel (5 + 1) strategy for the stereoselective construction of the cyclohexane core

  描述了一种由甲基酮和 1,5-二醇合成官能化环己烷的铱催化方法。该过程通过两个连续的借氢反应进行，可直接获得具有高度立体控制的多取代环状产物。这种方法代表了一种新颖的 (5 + 1) 策略，用于环己烷核心的立体选择性构建。
• Stereoselective synthesis of alicyclic ketones: A hydrogen borrowing approach
  作者：Roly J. Armstrong、Wasim M. Akhtar、James R. Frost、Kirsten E. Christensen、Neil G. Stevenson、Timothy J. Donohoe

  DOI：10.1016/j.tet.2019.130680

  日期：2019.11

  A highly diastereoselective annulation strategy for the synthesis of alicyclic ketones from diols and pentamethylacetophenone is described. This process is mediated by a commercially available iridium(III) catalyst, and provides efficient access to a wide range of cyclopentane and cyclohexane products with high levels of stereoselectivity. The origins of diastereoselectivity in the annulation reaction

  描述了一种由二醇和五甲基苯乙酮合成脂环族酮的高度非对映选择性环化策略。该方法由可商购的铱（III）催化剂介导，可有效地获得各种具有高立体选择性的环戊烷和环己烷产品。通过一系列控制实验探索了环空反应中非对映选择性的起源，这为如何控制新锻造环周围的每个立体中心提供了解释。
• [EN] CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS<br/>[FR] LIEURS P1 CYCLIQUES EN TANT QU'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013022814A1

  公开（公告）日：2013-02-14

  The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了化合物的结构式（Ia）：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽原的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• Synthesis and Biological Evaluation of Amide Derivatives of (6-Chloro-2,3-dihydro-1H-inden-1-yl)acetic Acid as Potential Anti-inflammatory Agents with Lower Gastrointestinal Toxicity
  作者：Meenakshi Sharma、Saumendra Mohan Ray

  DOI：10.1248/cpb.56.626

  日期：——

  A variety of amide derivatives of (6-chloro-2,3-dihydro-1H-inden-1-yl)acetic acid were synthesized and screened for their anti-inflammatory and related biological activities. These compounds were found to be longer acting and showed residual activity exceeding that of standard indomethacin. The studies with SKF-525A, a standard hepatic microsomal enzyme inhibitor showed that probably the test compound

  合成了多种（6-氯-2,3-二氢-1H-茚满-1-基）乙酸的酰胺衍生物，并筛选了它们的抗炎及相关生物活性。发现这些化合物作用时间更长，并且显示出超过标准消炎痛的残留活性。用标准肝微粒体酶抑制剂SKF-525A进行的研究表明，受试化合物本身可能是活性物质。化合物6y在ED30为6.45 mg / kg时表现出最佳的活性曲线，但是发现该化合物在100 mg / kg po下有毒。尽管这些化合物表现出明显的止痛和解热活性，但未能阻止佐剂诱导的继发性炎症的发展。关节炎分析。化合物6x显示出94％的乙酸诱导扭体抑制作用。研究表明，TNF-α的拮抗作用可能不涉及这些化合物的作用机理。然而，与消炎痛相比，在100 mg / kg po的测试剂量水平下，发现这些化合物仅具有轻度的致溃疡潜力。
• CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS
  申请人：Lam Patrick Y.S.

  公开号：US20140163002A1

  公开（公告）日：2014-06-12

  The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式(Ia)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆卡利肯双重抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞性和/或炎症性疾病的方法。